Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer

F.F.O. Rodrigues¹, R.E. Santos¹, M.B. Melo², M.A.L.G. Silva³, A.L. Oliveira¹, R.L. Rozenowicz³, L.B. Ulson¹ and T. Aoki¹

¹Departamento de Obstetrícia e Ginecologia, Santa Casa de São Paulo, Faculdade de Ciências Médicas, São Paulo, SP, Brasil
²Laboratório de Medicina Molecular, Departamento de Ciências Fisiológicas, Santa Casa de São Paulo, Faculdade de Ciências Médicas, São Paulo, SP, Brasil
³Departamento de Patologia, Santa Casa de São Paulo, Faculdade de Ciências Médicas, São Paulo, SP, Brasil

Corresponding author: F.F.O. Rodrigues
E-mail: foliveirarodrigues@uol.com.br

Received November 15, 2007
Accepted December 27, 2007
Published February 19, 2008

ABSTRACT. Primary chemotherapy is a useful strategy for the treatment of locally advanced breast cancer and therefore allows in vivo evaluation of the action of cytotoxic drugs and the possibility of accomplishing conservative breast surgeries, as well as the early treatment of metastasis. Mechanisms of resistance to the drugs include the action of protein associated with the efflux of drugs from the intracellular environment hindering their activity; one of the most studied proteins is P-glycoprotein codified by the MDR-1 gene. The presence of polymorphisms can determine different physiological actions of these proteins, intervening with the
response of the drug’s action. We evaluated the presence of single nucleotide polymorphism (SNP) C3435T of the MDR-1 gene and its correlation with the response to primary chemotherapy using the RECIST criteria. Forty-one Brazilian women with stages II and III breast cancer using the PCR-RFLP analysis were evaluated. Thirty-three patients with the SNP genotype (TT and CT) and eight patients with the wild genotype (CC) were found; there was no statistically significant correlation between the diverse genotypes and the clinical and pathological responses according to the Cramer correlation coefficient (V = 0.14). The parameters: nuclear and histological degree, and estrogens, progesterone and c-erb B2 receptors did not demonstrate a statistical correlation with the SNP C3435T. Patients with complete pathological response (12.5%) showed only the polymorphic genotype and not the wild genotype. The characteristics of miscegenation in our population could explain the absence of the characterization of a sub-group of individuals where the presence of the polymorphic genotype influenced the response to the primary chemotherapy.

Key words: Polymorphism; P-glycoprotein; Chemotherapy; Breast cancer